Robert Iannone - 16 Jan 2026 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
EVP, Global Head of R&D & CMO
Signature
By: /s/Paz Dizon, as attorney in fact For: Robert Iannone
Issuer symbol
JAZZ
Transactions as of
16 Jan 2026
Net transactions value
-$708,602
Form type
4
Filing time
21 Jan 2026, 19:53:17 UTC
Previous filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Iannone Robert EVP, Global Head of R&D & CMO 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, IRELAND By: /s/Paz Dizon, as attorney in fact For: Robert Iannone 21 Jan 2026 0001737329

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Award $0 +11,699 +16% $0.000000 84,398 16 Jan 2026 Direct F1, F2
transaction JAZZ Ordinary Shares Tax liability $708,602 -4,140 -4.9% $171.16 80,258 16 Jan 2026 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.
F2 The Reporting Person acquired 71 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025.
F3 Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations.